Liang Dai

1.4k citations
49 papers · 1.1k indexed · h-index 19
Topics
Liver Disease Diagnosis and Treatment (6 papers)interferon and immune responses (5 papers)Peroxisome Proliferator-Activated Receptors (5 papers)
Partner nations
ChinaSingaporeEthiopia

In The Last Decade

Liang Dai

47 papers receiving 1.1k citations

Peers

Liang Dai
Comparison fields: 5 of 100
  • Molecular Biology 627
  • Cancer Research 292
  • Immunology 246
  • Oncology 175
  • Plant Science 117
Replace Qianqian Yin with:
Qianqian Yin China
Yin Sun China
Robert Wild United States
Wenhua Lu China
Kulthida Vaeteewoottacharn Thailand
Zhe Liu China
Xiangxuan Zhao China
Lei Hu China
Ronghua Zhang China
Liang Dai relative to Qianqian Yin China Qianqian Yin's profile →
Citations per field
00.5×1.5×2.0×
Qianqian Yin · 1×
Citations per year

Countries citing papers authored by Liang Dai

Since Specialization
Citations

This map shows the geographic impact of Liang Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liang Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liang Dai more than expected).

Fields of papers citing papers by Liang Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liang Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liang Dai. The network helps show where Liang Dai may publish in the future.

Co-authorship network of co-authors of Liang Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Liang Dai. A scholar is included among the top collaborators of Liang Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liang Dai. Liang Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 8
3 1
4 2
5 4
6 9
7 9
8 2
9 8
10 16
11 37
12 49
13
Genome-scale CRISPR activation screening identifies a role of ELAVL2-CDKN1A axis in paclitaxel resistance in esophageal squamous cell carcinoma.
24
14 17
15 3
16 39
17 31
18 19
19 148
20 63

About Liang Dai

Liang Dai is a scholar working on Cancer Research, Complementary and alternative medicine and Family Practice, having authored 49 papers that have together received 1.1k indexed citations. Recurring topics across this work include Liver Disease Diagnosis and Treatment (6 papers), interferon and immune responses (5 papers) and Peroxisome Proliferator-Activated Receptors (5 papers). The work is most often cited by research in Cancer Research (292 citations), Immunology (246 citations) and Molecular Biology (627 citations). Liang Dai has collaborated with scholars based in China, Singapore and Ethiopia. Frequent co-authors include Xinyu Liu, Peter Cheung, Chan Aye Thu, Xiaoan Wen, Haoliang Yuan, Hongbin Sun, Wanpu Yan, Xiaozheng Kang, Caiping Chen and Bin Dong. Their work appears in journals such as Journal of the American Chemical Society, PLoS ONE and Biochemical Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026